Testing effectiveness (Phase 2)Active Not RecruitingNCT03719430What this trial is testingAPX005M and Doxorubicin in Advanced SarcomaWho this might be right forSoft Tissue Sarcoma Alexander Z. Wei, MD 27
Large-scale testing (Phase 3)Active Not RecruitingNCT04994132What this trial is testingCompare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk RhabdomyosarcomaWho this might be right forAlveolar RhabdomyosarcomaBotryoid-Type Embryonal RhabdomyosarcomaEmbryonal Rhabdomyosarcoma+5 more Children's Oncology Group 118
Testing effectiveness (Phase 2)Study completedNCT00661609What this trial is testingA Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder CancerWho this might be right forBladder CancerTransitional Cell Bladder CancerUrethra Cancer+2 more AstraZeneca 54
Testing effectiveness (Phase 2)Study completedNCT00949325What this trial is testingSafety and Efficacy Study of Torisel and Liposomal Doxorubicin for Patients With Recurrent SarcomaWho this might be right forSarcoma Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 24
Large-scale testing (Phase 3)Looking for participantsNCT05304585What this trial is testingChemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative RhabdomyosarcomaWho this might be right forEmbryonal RhabdomyosarcomaFusion-Negative Alveolar RhabdomyosarcomaSpindle Cell/Sclerosing Rhabdomyosarcoma Children's Oncology Group 205
Testing effectiveness (Phase 2)Looking for participantsNCT02734537What this trial is testingRadiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone SurgeryWho this might be right forHead and Neck Squamous Cell CarcinomaHypopharyngeal Squamous Cell CarcinomaLaryngeal Squamous Cell Carcinoma+13 more ECOG-ACRIN Cancer Research Group 189
Large-scale testing (Phase 3)Looking for participantsNCT06568172What this trial is testingTesting the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin CancerWho this might be right forEyelid Squamous Cell CarcinomaRecurrent Eyelid Squamous Cell CarcinomaRecurrent Skin Acantholytic Squamous Cell Carcinoma+17 more National Cancer Institute (NCI) 420
Not applicableUnknownNCT04353050What this trial is testingAtypical MOLes and Melanoma Early Detection Study (MoleMed)Who this might be right forMelanomaMelanoma (Skin)Moles+9 more Russian Academy of Medical Sciences 350
Not applicableStudy completedNCT02986503What this trial is testingEuropean Study in Bone Sarcoma Patients Over 40 YearsWho this might be right forSpindle Cell Sarcoma of BoneOsteosarcoma Italian Sarcoma Group 100
Testing effectiveness (Phase 2)WithdrawnNCT04906876What this trial is testing9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced SarcomasWho this might be right forSarcomaSoft Tissue SarcomaMetastatic Sarcoma+10 more Brown University
Not applicableNot Yet RecruitingNCT06526897What this trial is testingEvaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue SarcomaWho this might be right forAdult Pleomorphic RhabdomyosarcomaAJCC Grade 2 SarcomaAJCC Grade 3 Sarcoma+20 more ECOG-ACRIN Cancer Research Group 1,582
Not applicableUnknownNCT05402046What this trial is testingClinical vAlidation of a MobilE appLication ("ProRodinki") in the Assessment of the maLignant skIn neoplAsmsWho this might be right forMelanoma (Skin)NevusNevus, Spitz+7 more MelanomaPRO, Russia 605
Testing effectiveness (Phase 2)Active Not RecruitingNCT02834013What this trial is testingNivolumab and Ipilimumab in Treating Patients With Rare TumorsWho this might be right forAcinar Cell CarcinomaAdenoid Cystic CarcinomaAdrenal Cortical Carcinoma+91 more National Cancer Institute (NCI) 818
Testing effectiveness (Phase 2)Looking for participantsNCT06239272What this trial is testingNRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)Who this might be right forAdipocytic NeoplasmLiposarcomaAtypical Fibroxanthoma+6 more St. Jude Children's Research Hospital 139
Large-scale testing (Phase 3)Study completedNCT00075582What this trial is testingVincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk RhabdomyosarcomaWho this might be right forAdult RhabdomyosarcomaEmbryonal Childhood RhabdomyosarcomaEmbryonal-botryoid Childhood Rhabdomyosarcoma+1 more Children's Oncology Group 390
Early research (Phase 1)Active Not RecruitingNCT04420975What this trial is testingNivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue SarcomaWho this might be right forLeiomyosarcomaMalignant Peripheral Nerve Sheath TumorMyxofibrosarcoma+27 more Jonsson Comprehensive Cancer Center 14
Testing effectiveness (Phase 2)WithdrawnNCT05116800What this trial is testingPhase 2 Study of 9-ING-41 With Chemotherapy in SarcomaWho this might be right forSoft Tissue SarcomaUndifferentiated Pleomorphic SarcomaMyxofibrosarcoma+10 more Brown University
Large-scale testing (Phase 3)Active Not RecruitingNCT02567435What this trial is testingCombination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk RhabdomyosarcomaWho this might be right forAlveolar RhabdomyosarcomaBotryoid-Type Embryonal RhabdomyosarcomaEmbryonal Rhabdomyosarcoma+3 more National Cancer Institute (NCI) 325
Testing effectiveness (Phase 2)Ended earlyNCT02022358What this trial is testingWill Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays?Who this might be right forOsteosarcomaSpindle Cell Sarcoma of Bone University College, London 34
Not applicableLooking for participantsNCT05463796What this trial is testingInAdvance: Surveillance, Prevention, and Interception in a Population at Risk for CancerWho this might be right forCancer RiskCancer Predisposition SyndromeHereditary Cancer Prediction+28 more Dana-Farber Cancer Institute 5,000